favor stronger oper profil name momentum
unwind
expect ep declin y/i
med-tech remain growth mani investor ep expect
grow even rel under-perform med-tech recent session
dial back expect head portfolio management
perspect favor long-short strategi momentum continu unwind
trade place procedur multipl survey kol call spine joint recon
ophtho suggest volum stabl physician expect continu stabil
ye think investor awar idiosyncrat nuanc extra
sell day tougher comp lead less volatil taken togeth think
name best opportun outperform reason
expect easier comp stronger oper profil head earn
favor alc quarterli beat
cautiou less certain
see name like come in-lin expect rais pt
lower pt result recent
name prefer alcon alc neutral zimmer biomet buy
buy pt alc combin easier
comp across segment combin panoptix launch believ
progress well recent pullback share set favor
risk/reward face challeng comp benefit extra sell day
 combin new product launch robust rosa demand
believ excit investor robot competit
increas street estim robot reason spine market
stabl continu hire rep rapid pace make us think
could sustain continu market implant gain face less
challeng comp insid buy share wound player
continu benefit competit weak wound market lastli
challeng comp believ upsid
recent orthex acquisit small benefit could move growth
see risk buy pt buy pt
neutral orthofix neutral new product
power growth engin face challeng comp multipl key segment
name knee neurotech instrument endoscopi worri beat
rais cadenc investor come expect may take breather
face challeng comp us hardwar us surgic support
investor appear concern street estim may high face
first doesnt fulli benefit cypass recal see street
estim high base underli istent growth rate continu
launch combin tough comp biostim legaci spine
perform strong dollar impact exfix could hamper
price target chang orthopediatr organogenesi
roll forward estim rais pt also lower
price target reflect recent warrant
exchang chang underli thesi
tabl content
preview model revenu y/i y/i organ adjust ep consensu
expect call place us line street segment model
orthopaed y/i includ knee y/i hip y/i trauma
extrem y/i y/i medsurg y/i includ
instrument y/i endoscopi y/i medic y/i sustain
y/i neurotechnolog spine y/i compris neurotechnolog
spine y/i y/i pro-forma consensu estim segment revenu
orthopaed knee hip trauma extrem
medsurg instrument endoscopi medic sustain
neurotechnolog spine neurotechnolog spine geographi model revenu
y/i us y/i ou street trauma
post strong result post organ sale growth
respect rais organ growth guidanc quarter current stand rang initi
rang midpoint updat guidanc impli organ growth think
achiev slightli concern comp across varieti segment difficult includ knee instrument
endoscopi neurotech
look orthopaed easiest result xfx basi segment lap hip
forecast improv result sub-seg drive acceler broader orthoped growth certain
improv hip result mako sale volatil inclus competit entrant
uncertain whether mako sale cycl may elong although management reiter see impact
evolut mako dynam rosa market close watch two question aris
rosa one introduct competit system impact mako sale two impact
abil gain share knee primarili hip implant competit account initi check system
initi discuss kol indic focus initi commerci effort rosa high volum
implant user lead us believ like see elev competit mako placement
first sever quarter rosa roll-out focus account note past
place system competit account find unlik place system account
share feel much way direct competit placement initi similar vein
larg exist instal base util continu increas anticip rosa impact
abil gain market share implant initi commerci one concern come
first sequenti declin util mako saw posit resumpt upward trend
util increas sequenti procedures/unit still rate
seen repres increas compar y/i period expect trend continu
dynam medsurg neurotechnolog spine mix orthopaed medsurg face
difficult comp xfx management vocal product cadenc support continu momentum medsurg
name power tool new camera adopt dispos product growth medic cautiou
quarter big question neurotechnolog spine continu perform spine on-going
integr management continu expect pro-forma growth spine year forecast
number still ahead consensu sequenti deceler us spine result management comment
call us sale exit quarter msd indic potenti upsid estim
share rel flat past quarter roughli in-lin ihi ntm ep
share trade closer histor premium large-cap peer higher group ntm ep see
share like remain valuat level print expect much beat quarter
expect share pull-back current level could see share stagnant clearer pictur emerg
around guidanc impact rosa mako
model chang adjust model recent currenc fluctuat
valuat stryker rate buy pt base month adjust ep estim
believ consist execut above-market organ growth improv margin profil warrant premium
valuat multipl peer see multipl signific premium given syk rel valuat larg
cap peer risk relat rate pt includ acquisit proceed expect acquisit limit om
growth increas competit robot softer market specif segment
btig research estim compani filingsnewold changentm laboratoriesabtneutr inc baxnot dickinsonbdxnot scientificbsxbuy lifesciencesewneutr nephew adrsnnnot factset data btig research estim ex-amortcompanytickerr ptpricemarket cap bev/salesev/ebitdacagr
incom etot y/i sale special oper incom incom tax expens net incom share net incom share gross oper expens btig research estim compani report
revenu y/i q/q mixdomest btig research estim compani report
preview model revenu y/i y/i xfx ifr ep adj ep
consensu expect call revenu ifr lp adj ep line
street top line adjust ep ahead ifr ep segment model y/i y/i
xfx surgic compris y/i y/i y/i consum
implant equipment/oth respect within vision model y/i y/i xfx
compos y/i y/i contact lens ocular health respect
geograph model us revenu y/i y/i y/i xfx
head quarter posit bias toward alc beat expect comp within surgic easier
theyv previou two quarter notabl within implant equip put strong growth
xfx respect consum face sequenti higher comp launch panoptix
sure impact result physician may wait use new len came sidelin
expect modest bump initi panoptix use believ key focu investor quarter given
much alc premium valuat predic success panoptix notabl initi show
increas premium at-iol share signific growth impact consum segment
equat improv overal growth alc recent catch management european societi
cataract refract surgeon indic us surgeon use panoptix may wait see
patient respond jump head first trifoc turn vision note tougher comp contact
lens ocular health come stellar quarter although admittedli less line sight
segment busi
believ big focu around oper margin given alc spend level recal alc
post adj om annual guidanc management assur us would high
point around product launch spend notabl panoptix launch remain cautiou see om
come low end guidanc given sap implement along spend level like abat
view
alc valuat gotten modestli attract share sit ntm ep last
quarter still remain rel elev compar larg cap med-tech broadli ntm ep think
broader macroeconom pressur weigh share in-lin pressur larg cap med-tech alc still
sit ihi like seen defens name market choppi weve receiv inbound
call generalist investor look name given well held rel peer
model chang adjust model updat currenc brought total sale slightli
beyond
valuat alcon rate neutral alc share current trade ntm price-to-earnings vs large-cap medic technolog
peer trade forecast alc grow revenu compound-annual-growth-rate ep compound-annual-growth-rate rel
peer averag respect feel premium warrant share current valuat
net gross ebit btig research estim compani filingsnewold chang
leav littl room increas multipl much bull case seem price alcon btig provid price
target neutral-r stock risk rate includ weaker expect economi may drive slower growth over-the-counter
segment delay product rollout signific competit variou busi segment margin expans take longer
expect increas liabil associ cypass upsid risk includ product growth move faster expect
new product adopt go faster expect strength bull market support higher multipl margin
improv progress faster anticip
ntm laboratoriesabtneutr inc baxnot dickinsonbdxnot scientificbsxbuy companiescoonot lifesciencesewneutr nephew adrsnnnot varbuy biometzbhbuy factset data btig estim ex-amortev/salescagrcompanytickerr ptpricemarket cap
alc incom etot y/i sale sale profit oper incom incom loss financi incom incom tax expens incom share gross gross gross gross oper oper pre-tax pre-tax net net adjust sg oper oper btig research estim compani report
alc revenu erevenuessurg contact ocular mixunit growthsurg contact ocular y/i growthunit growthsurg contact ocular growthunit mixsurg contact ocular mixunit btig research estim compani report
preview model revenu y/i y/i xfx adjust ep consensu
expect call put us essenti line consensu top line bottom line
segment model knee y/i hip y/i y/i
dental y/i spine cmf y/i y/i consensu estim
segment break knee hip dental spine
cmf geograph revenu mix america emea
asia pacif consensu geograph mix us emea asia pacif
recent upgrad share follow survey physician interest rosa assess
implant custom base gain deeper understand well compani target custom base
result resoundingli posit believ good direct assess head felt
earli momentum rosa upsid estim even comp difficult see
opportun beat base earli momentum top-line guidanc call xfx growth
impli growth current estim growth move
benefit extra bill day though off-set revenu rebat
arguabl import aspect zbh result on-going launch rosa system management disclos
minim number system deploy discuss kol describ compani
initi target devic develop larg exclus account initi deploy system
valid survey result expand roll-out rosa curiou see pent-up
demand system though expect signific capit revenu launch expand full
roll-out broadli knee expect see improv result roll new cementless knee implant
forecast continu acceler knee growth xfx note estim
inclus rosa sale management expect provid color rosa impact growth number allow
investor see whether grow knee implant busi in-lin market still lose share also expect
see increment improv price segment cementless offer rosa take greater hold
outsid rosa knee feel segment interest investor dental spine dental
bright spot year post first posit quarterli growth xfx invest compani
made begin pay expect momentum continu potenti upsid look
management announc plan begin special sale forc delin sportsm variou extrem categori
current anticip slight deceler feel could go either way see disrupt
sale realign rapid realiz product gain possibl within spine
disappoint year continu feel franchis struggl saw littl nass indic
divis begin experi sustain turnaround current forecast return y/i growth see
potenti downsid number
current forecast essenti flat vs feel could upsid
number line call management discuss expect step gm driven
particular medic devic excis tax refund benefit mix reduc qualiti remedi expens
also benefit opex differ stori forecast elev sg expens
view unlik abat compani push new initi sale forc work valid
zbh valuat remain large-cap peer share trade ntm price-to-earnings vs peer trade ntm
price-to-earnings see upsid share given multipl believ rosa success growth go higher ep
like follow current forecast revenu ep compound-annual-growth-rate
model chang chang model recent upgrad share latest estim fx built
valuat zimmer biomet rate buy pt base month ep estim
seen multipl numer year consid rel valuat ihi ntm price-to-earnings basi
prior transform compani would typic trade ihi rel basi impli
reason multipl risk rate pt includ loss market share competitor inabl remov risk
relat manufactur slower rosa commerci anticip lack consist execut goal
lack margin expans due increas invest
ntm laboratoriesabtneutr inc baxnot dickinsonbdxnot scientificbsxbuy lifesciencesewneutr nephew adrsnnnot varbuy biometzbhbuy factset data btig estim ptpricemarket cap bev/ebitdap/ ex-amortev/salescagr
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
preview head model revenu y/i y/i organ adjust ep
adjust ebitda consensu expect call revenu adjust ep adjust
ebitda revenu segment model codman specialti surgic revenu y/i
orthoped tissu technolog revenu y/i consensu expect call codman specialti
surgic revenu orthoped tissu technolog revenu ahead consensu
css behind consensu ott line ep ahead adj ebitda
model organ growth larg driven growth extrem orthoped turn around
quarter faster expect hsd growth wound reconstruct lsd msd growth css specif
subseg perform advanc dural repair note easier comp css combin extrem
orthoped off-set tougher comp regen technolog believ mani new product management
discuss cerelink icp monitor certa hydrocephalu stent integra duo headlamp
meaning impact combin recent launch product ott segment addit sale forc
integr within css rear-view mirror believ investor final get clear pictur around capabl
combin sale forc healthi new product cadenc given improv organ growth
find difficult believ slow meaning easier comp said enthusiasm
temper somewhat notabl item first management cite new competit product launch advanc
syk sonopet dural repair syk adheru dural sealant formerli hyperbranch collect could elong
capit sale cusa impact iart dural repair franchis
turn orthoped tissu technolog extrem orthoped face easier comp
regen difficult mid-teen comp believ improv perform new
product panta medihoney help power ott segment respect msd perform
importantli consensu expect segment fairli in-lin quarterli guidanc estim
wiggl room meet organ guidanc note privat label order
pull forward may also diminish perform
 perspect expect direct commentari new cfo carri come industri
manufactur space drive long-term investor expect expect anyth neg
walk back target instead expect carri pick previou cfo glenn coleman left name margin
improv initi around manufactur sku ration erp consolid etc codman integr
behind expect investor begin see save start help improv adj ebitda
turn valuat share sit ntm price-to-earnings rel peer trade ntm price-to-earnings recogn
grow peer continu see opportun multipl expans top bottom line improv
model chang chang model time
valuat integra rate buy pt base project month estim ep current
trade estim ntm ep project versu comp group forecast revenu compound-annual-growth-rate
comp group forecast ep compound-annual-growth-rate
comp group believ appropri given expect improv growth multipl
quarter still maintain discount comp group slower overal revenu growth risk rate pt
includ softer expect organ growth current momentum med-tech market integr risk codman
competit select market product mix impact gross margin slower expect sale forc product
ntm lifesciencesewneutr medicalmmsinot medicalwmginot lifesciencesiartbuy factset data btig research estim ex-amortev/salesev/ebitdacagrcompanytickerr ptpricemarket cap
incom etot y/i sale time oper incom incom tax expens net incom share net incom gross net net oper expens btig research estim compani report
revenu ecodman specialti tissu growthcodman specialti tissu growthcodman specialti tissu btig estim compani report
preview model revenu y/i report organ adjust ep consensu
expect call segment model musculoskelet product spine trauma
emerg technolog revenu y/i growth y/i growth equival system plu
servic revenu consensu expect call musculoskelet emerg technolog revenu
respect us/ou split consensu us/ou split call revenu
respect line consensu musculoskelet behind emerg technolog
slightli behind ep
initi point view would struggl maintain growth rate maintain margin follow
result initi assumpt play elev rep hire new set deploy
weigh sg subsequ adj ebitda saw increas invest robot drag
ebitda margin invest requir set rep peripher market segment
imag larg joint reconstruct robot ultim sold lower see margin pressur
abat see situat like maintain top line momentum expens adj ebitda margin
compani branch new market segment call bp y/i compress gm bp
increas sg percentag revenu current call bp declin percentag
revenu declin feel could come higher base aggreg level
top-line forecast deceler growth across busi within
musculoskelet forecast increas growth y/i declin q/q driven signific
out-performance spinal hardwar feel abl maintain top-line growth within spinal implant new
set rep abl continu drive growth within number feel could upsid trauma
management said beat estim sever million new trauma system releas intra-quart sale
forc manufactur larg place feel divis abl maintain momentum
caught management nass note trauma like inflect higher revenu could
emerg technolog robot forecast excelsiusgp system sale ten
five dynam around system muddl unit sold compar
system sold though pent demand particularli make comp difficult fulli judg
said management describ elong sale cycl feel due increas competit trial competit
system like benefit investor eye later expect launch nuva puls robot system
dynam unlik abat doctor introduc puls zbh futur rosa spine robot
applic hospit may delay purchas system anticip system combin medtron
continu momentum said consensu expect emerg technolog measur rel
previou quarter see less room disappoint segment suggest us beat expect
quarter continu musculoskelet momentum
lastli valuat continu appear balanc context increas competit decreas margin
limit ep growth trade ntm price-to-earnings vs peer trade ntm price-to-earnings ebitda basi
trade ntm ev/ebitda compar peer trade ntm ev/ebitda
model chang leav model unchang time
valuat rate neutral share reflect balanc risk/reward context increas robot
competit declin margin increas oper expens share current trade ntm price-to-earnings
ev/ebitda compar peer trade ep ev/ebitda btig publish price target
neutral rate stock risk rate includ competit sale forc retent increase/slowdown spine
procedur better expens manag anticip benefit robot spinal hardwar sale hospit capital-expenditure
budget constraint reimburs chang within spine price pressur concentr vote control
ntm lifesciencesewneutr lifesciencesiartbuy medicalmmsinot factset data btig research estim ptpricemarket cap bp/e ex-amortev/salesev/ebitdacagr
incom etot y/i sale time oper incom incom tax expens net incom share gaap net incom oper expens btig research estim compani report
revenu emusculoskelet growthmusculoskelet growthmusculoskelet splitmusculoskelet btig estim compani report
preview head model revenu y/i y/i xfx adjust ep adjust
oper incom adjust ebitda consensu expect call revenu ep
adjust oper incom adjust ebitda segment model us spinal hardwar
us surgic support includ puerto rico y/i y/i
y/i y/i xfx respect consensu expect us spinal hardwar us
surgic support call respect slightli ahead
street revenu across segment slightli behind ep oper incom adjust ebitda
share sold follow nass compani reveal robot extens puls system
feel investor appreci function system somewhat disappoint timelin
commerci robot management expect begin feel system offer compel
function price still littl add beta test would qualifi next gener
system commerci system without robot capabl remain underway continu feel
system even without robot arm offer compel valu proposit hospit
establish futur robot arm add-on push cost competit system would cost hospit
feel doctor hospit option buy featur puls futur upsid robot without
risk higher cost mitig technolog obsolesc risk
move revenu expect forecast sequenti acceler overal top-line growth
difficult comp us off-set significantli easier comp intern look us hardwar
lap difficult comp year forecast sequenti deceler growth segment
said result beat estim growth acceler prior year strong roll-out given
interest saw later procedur nass feel room run could potenti lead
upsid segment us surgic support forecast growth difficult comp
forecast call acceler declin feel lap biolog weak
improv stabil nc abat difficult comp provid tailwind comp
eas growth growth fx similarli tailwind report number
feel reduct guidanc somewhat derisk number lower expect said
somewhat cautiou print given comp us spinal hardwar us surgic support
combin consensu expect sit closer higher end guidanc
margin forecast continu improv gm y/i mix continu improv west
carrolton plant continu on-board capac nuva analyst day august management establish guidanc
om take sale om gain larg back end load time near-term
invest oper leverag notabl sg new product roll-out new product develop
valuat continu remain attract rel peer continu trade discount result
slower top-lin growth delay margin expans multipl remain fairli depress current trade
ntm price-to-earnings compar peer ntm price-to-earnings ntm ev/ebitda vs peer ntm ev/ebitda
model chang leav model unchang time
valuat rate buy pt base split valuat price-to-earnings ev/ebitda price-to-earnings basi
use month ep estim ev/ebitda basi use month ebitda estim risk
relat rate pt includ competit slowdown spine procedur product develop timelin
oper execut manufactur product challeng intern slow subsequ recoveri
acquisit fail improv growth
ntm lifesciencesewneutr lifesciencesiartbuy surgicalisrgneutr medicalmmsinot factset data btig research estim ex-amortev/salescagrev/ebitdacompanytickerr ptpricemarket cap
incom etot y/i sale time oper incom expens incom tax expens net incom share net incom share net net oper expens btig research estim compani report
revenu eu spinal hardwar surgic support includ includ growthu spinal hardwar surgic support includ includ growthu spinal hardwar surgic support includ includ splitu spinal hardwar surgic support includ btig estim compani report
preview model revenu y/i ebitda lp consensu estim call
revenu ebitda lp geographi model us revenu y/i
ou revenu y/i y/i xfx consensu estim call us revenu ou
revenu slightli ahead consensu revenu come behind ebitda line lp
follow call saw whirlwind news headlin acquisit avedro share sold
view due acquisit dilut call question management belief compani abil lap
increasingli difficult comp think acquisit also rais concern weve previous written
long-term viabil legaci pipelin acquisit news larg overshadow oper result
feel updat avedro legaci pipelin main concern investor head
avedro oper result key updat guidanc view guidanc street
consensu current call revenu respect avedro
impli deceler growth revenu expect grow y/i deceler
y/i estim contribut broader growth
assum avedro acquisit close midway outsid top-line expect origin forecast
cost synergi addit revenu synergi begin transact although expect
come cost synergi base preliminari analysi combin entiti
beyond avedro acquisit less heavili focus second consecut conserv guidanc increas
follow quarterli beat revenu despit top-line beat guidanc rais intern
guidanc rais midpoint guidanc impli us ou growth
midpoint cypass recal lap given management belief mig market continu grow mid-teen
guidanc put istent growth essenti line market assum sever percent gain also realiz
inject price sever put take feel could impact near term result istent franchis
check continu indic compani fulli shift legaci istent usag inject management continu
describ situat exist volum convert regardless rep freed go
return hunt account would expect inject share taker grow excess market potenti
leav upsid revenu estim kol call host told dr jacob brubak
glaucoma specialist user inject ivanti hydru competit trial continu go slowli
feel could provid cushion despit posit expect drag nh reimburs cut
fulli felt ou sale may felt strongli
beyond immedi commerci result pipelin updat close watch abl get look new
istent inject similar inject implant wider anchor flang better hold implant place escr
feel devic like trial eu potenti us entri though given
inform timelin price legaci pipelin interest remain focus idos specif
month data ph ii trial management announc hand call disclos well
greater inform differ idos formul announc call discuss dr
support skeptic abil invas implant becom market domin first line treatment
product pipelin remain tangenti key invest thesi us question
share volatil past quarter sit ntm sale rel peer trade
investor move away high multipl growth stock share pressur reluct
come sidelin given limit chang fundament stori acknowledg share
significantli cheaper time
model chang made chang model time
valuat rate neutral trade estim next twelve-month revenu project vs
comp group comp group compos similar high growth high multipl medic technolog
compani forecast revenu growth comp group project grow
believ product offer novel solut treatment variou form glaucoma growth
near term constrain limit applic combin cataract procedur physician feedback mix
valuat reflect sizabl premium share result futur product btig publish price target
neutral rate stock risk rate includ competit exist new player devic
pharmaceut clinic efficaci pipelin product physician reimburs risk price eros on-go patent
ntm entxentneutr medicaltcmdneutr medicalwmginot factset data btig research estim ex-amortev/salescagrev/ebitdacompanytickerr ptpricemarket cap
incom etot y/i sale oper incom incom tax expens net incom share oper expens btig research estim compani report
revenu eproduct growthu growth growth btig estim compani report
preview model revenu y/i adjust ebitda adjust ep
consensu estim call revenu adjust ebitda adjust ep segment
model biostim revenu y/i biolog revenu y/i extrem fixat revenu
y/i spine fixat revenu y/i consensu estim call biostim biolog
extrem fixat spine fixat revenu respect essenti
line consensu across top bottom line
share remain larg flat follow result report remain sinc downgrad share
growth spend concern print continu extens result slightli beat
revenu amidst put take top-line elev expens drag earn move see
top-line continu uncertainti around expens management transit keep us
sidelin larg focu recent meet management reiter notion investor get
meaning pictur commerci like within januari around confer
look spine franchis biostim biolog spine fixat forecast biostim maintain growth level
forecast revers biolog deceler growth spine fixat acceler
declin growth dig result see potenti downsid biostim approach
difficult comp growth result bolu order biolog segment beat
expect first two quarter distributor win region turnaround new product ad
growth segment continu come easier comp declin management guidanc hsd
growth impli deceler leav estim line beatabl view spine fixat
commerci start strongli comp segment difficult spinal kinet benefit turn organ
feel poor result legaci spine busi could drive top-line toward low end guidanc within spinal
fixat look see surgeon train level us revenu product target
year gener june suggest could upsid full year guidanc
ramp progress plan wonder abil devic rapidli move beyond earli adopt
follow disrupt seen legaci distributor churn yet see real gain new distributor
hope see play
extrem fixat rebound result weak comp challeng difficult comp
back bolu order guidanc year lower result see room potenti downsid
estim especi dollar strengthen quarter
expens forecast notabl declin y/i opex revenu lower
expens off-set somewhat increas expens flatten regulatori cost associ bring
us market longer increas line though may off-set somewhat increas
 expens relat bring new distributor
note first call new ceo jon serbousek abl speak investor outgo ceo brad
still call transit curiou hear attract mr serbousek
posit vision compani move forward worri new ceo place compani could
use opportun reset expect previou comment mr mason made grow dd
organ follow launch
lastli valuat stand ntm price-to-earnings ntm ev/sal ntm ev/ebitda vs peer ntm price-to-earnings
ntm ev/sal ntm ev/ebitda sizabl discount peer across valuat metric though may
limit investor downsid continu feel without meaning acceler higher share like
remain rang bound quarter
model chang leav model unchang time
valuat rate neutral btig publish price target neutral-r stock risk rate includ
commerci integr spinal kinet biolog price pressur cost save initi
materi litig risk reimburs risk commerci payer distributor competit
ntm therapeuticsaniknot lifesciencesiartbuy surgicalrtixnot factset data btig research estim ptpricemarket cap bev/ebitdap/ ex-amortev/salescagr
incom y/i sale oper incom incom tax expens incom continu discontinu oper net incom share net incom continu op interest net net oper expens btig research estim compani report
revenu btig estim compani report
preview forecast revenu y/i lp includ total purapli revenu
y/i consensu estim call revenu lp put us slightli ahead
street revenu in-lin ep product famili forecast revenu y/i wound
y/i surgic sport medicin
follow two strong top-lin beat sinc initi spac transact feel confid compani
abl continu put strong result momentum continu guidanc conserv saw
compani top-line grow y/i midpoint guidanc increas follow first
second quarter respect back strength surgic sport medicin famili product
share languish somewhat lead warrant exchang follow exchang share appreci orgo stock
trade in-lin fundament head print note continu easier comp purapli lack pass-
statu well signific insid buy share open market
within wound product famili forecast growth driven signific gain purapli y/i
continu benefit reinstat pass-through statu discuss management recent roadshow
describ situat purapli current account view leav potenti upsid
beyond gain pass-through product significantli outpac expect
forecast similar deceler growth deceler growth given result start
year see room potenti upsid outsid purapli expect rep addit help bolster growth combin
increas amniot adopt management reiter confid amniot busi believ larg
larger purapli time
surgic sport medicin product famili forecast similar deceler prior
quarter despit beat past two quarter continu feel less visibl segment
quarterli basi grow sale forc could continu upsid number management kept guidanc
within sm conserv given young ish natur segment base previou result
respect see adopt
beyond top-line result continu monitor competit situat wound market follow
consolid earlier year also look updat around sale forc management describ us
roadshow benefit expans portfolio product compani direct rep
increas trail month independ distributor expect continu
increas curiou see competit dynam around rep hire compani announc
expand contract vizient prior quarter curiou see quickli management feel abl
orgo share somewhat rollercoast past quarter due warrant exchang share
return normal level trade ntm sale rel peer trade ntm sale
continu see opportun multipl expans acknowledg share hamper limit
float believ abil compani add float actual move share higher given interest hear
investor
model chang incorpor addit share warrant exchang also slightli tweak
interest expens outer year
valuat rate buy pt previous base month ev/sal estim
price target chang account updat share count result recent warrant exchang risk
rate pt includ loss pass-through statu competit wound care sector fda regulatori risk
wound market percept investor awar lack intellectu properti commerci payer dynam need
marginnmnmnmnmnmnmnmnmnm btig research estim compani filingsnewold changentm lifesciencesiartbuy medicalmmsinot nephewsnnnot medicalwmginot factset data btig research estim ex-amortev/salescagrcompanytickerr ptpricemarket cap
incom etot y/i sale time oper incom expens incom tax expens loss comprehens net incom share net net oper expens btig research estim compani report
revenu ewound sport medicin growthwound sport medicin growthwound sport medicin splitwound sport medicin btig estim compani report
preview forecast revenu y/i adj lp versu consensu expect
adj lp product model epicel sale y/i maci sale
y/i consensu expect call epicel maci sale respect forecast slightli
sale overal mix segment line lp
continu bullish despit choppi share follow management commentari call led
investor question season review recap management commentari around growth
season call y/i maci growth annual total come
investor concern result someth step previou estim
feel indic maci result slow may weak necessarili note
comp somewhat inflat price increas hit last year well import note given size
beat maci revenu elev revenu estim updat estim note
accur reflect season given biopsi strength seen increas convers rate
would expect management line sight next month revenu belief biopsi
particularli strong give management confid convers rather weak specif
feel would discuss earlier becam evid
surgeon dynam behind growth maci continu posit two-third growth come surgeon
user carticel target surgeon base increas feel factor
support confid still signific ramp maci revenu growth rep product increas
new opportun rep deepen penetr continu hire plan feel
concern season mitig multitud pathway continu maci revenu growth
long-term said near-term would use weak print acquir share expect result
bad fear like come in-lin upon print follow believ share could move higher
season strong show signific oper leverag also depend expect
remain appropri control may remain overhang near-term base investor convers
weve
move burn side busi forecast msd growth epicel despit come tough comp
y/i growth epicel revenu came line estim miss estim continu
feel potenti upsid product offer investor less evid increas competit
burn space said management highlight confid underli busi trend relat epicel
call expect meaning updat call relat time bla submiss approv
nexobrid kol call host provid encourag feedback usag efficaci
nexobrid kol describ competit environ essenti noth market provid
compar product belief nexobrid could becom mainstay burn center around countri provid
use point entri rep sell epicel
outsid direct sale result would expect management provid current think appropri size maci
sale forc like complet size exercis class maci rep hire recal management intent
bring largest bolu maci rep sinc maci approv
vericel share sit ntm ev/sal compar high-growth med-tech multipl ntm ev/sal --
valuat continu view attract given confid maci abil drive sustain growth multi-
model chang made slight tweak top-lin estim close align management commentari
around season maci
valuat rate buy price target base ev/sal multipli mo revenu
estim plu discount sale analysi futur nexobrid sale believ multipl fair
belong higher growth comp group compris fast-growth med-tech compani higher growth comp group
current trade ev/sal ev/sal indic appli discount vcel
valuat multipl believ discount appropri slightli lower growth revenu compound-annual-growth-rate
rest higher growth group risk rate price target includ limit ip competit non-aci
compani increas competit burn market bla submiss subsequ approv nexobrid market
develop burn cartilag repair product sale cadenc potenti capit dilut
net ebit btig research estim compani filingsnewold changentm entxent neutral surgicalisrgneutr technologiesirtcbuy pt medicaltcmdbuy pt medicalwmginot factset data btig research estim ptpricemarket cap bp/e ex-amortev/salescagr
incom etot y/i sale oper incom incom tax expens net incom share net incom share net oper expens btig research estim compani report
revenu eproduct btig estim compani report
preview model revenu y/i adjust ebitda adjust lp consensu
expect call revenu adjust ebitda adjust lp place us larg line
street segment model revenu y/i trauma deform y/i scoliosi
y/i sport medicine/oth
share appreci sinc last quarterli call settl top-line guidanc
increas impli y/i growth midpoint current fall
y/i growth year
see trauma deform lead growth orthex acquisit begin provid
substanti benefit organ feel cautious optimist possibl upsid revenu
updat guidanc assum minim growth acquir orthex asset acquir disclos
orthex gener revenu equat revenu account minim
amount adult procedur number return guidanc increas midpoint yield estim
dollar valu increas less assum acquir revenu addit disclos financi
first month orthex suggest higher annual run-rat closer state management
commentari indic desir cautiou due transit dynam combin lumpi natur
orthex busi potenti lead imperfect revenu match vs said bolu orthex set
deploy shortli june acquisit first wave rep like complet train orthex product
 feel possibl sale begin increas along greater distribut though may
event addit rep get train
see mix dynam scoliosi model slight acceler y/i growth follow sequenti
deceler segment come toughest comp year grow y/i
drive high bar make risk/reward look less compel valuat exclus orthex feel
greater distribut continu help off-set small statur system enter second summer
quarter busiest procedur period year juli august school month system abl
beyond top-line investor interest dynam around disposit vilex asset cash dynam
compani initi laid plan sell legaci adult vilex asset describ sever unsolicit
notif interest call time call come would expect management specif timelin
inform potenti sale asset along would expect updat management cash
posit inform termin term loan squadron capit fee vilex disposit
potenti initi plan set deploy legaci busi new orthex busi updat
investor look growth sale forc domest intern updat
commerci organ new leadership hire updat product portfolio name surgic plan softwar
orthex chang intern distribut format
lastli valuat perspect share continu trade premium small-cap orthoped discount
high-growth medic technolog peer specif trade ntm ev/sal versu ntm ev/sal
small-cap orthoped high-growth medic technolog peer respect feel appropri comparison
high-growth medic technolog peer given larg market opportun lack competit continu execut
said miss expect unabl grow assum level either orthex legaci
busi share pressur
model chang leav model unchang time
valuat rate buy pt base month estim revenu risk
price target rate includ competit larger entrench orthoped compani slowdown
product pipelin loss key physician custom loss key distributor sale agent lack intellectu
properti long-term clinic data
ntm entxentneutr surgicalisrgneutr technologiesirtcbuy pt factset data btig research estim ptpricemarket cap bp/e ex-amortev/salescagr
y/i gross gross profit gener research one time charges- total oper expens incom pre-tax incom tax benefit net incom adj net incom loss adj ep share ebitda incom tax oper btig research estim compani report
revenu growthtrauma growthtrauma btig research estim compani report
preview model revenu y/i adjust ebitda adjust lp
consensu estim call revenu adjust ebitda adjust lp product
model avanc revenu y/i axoguard revenu y/i aviv revenu
y/i other/intern revenu y/i slightli ahead revenu adj lp
behind adj ebitda
guidanc narrow reduc call lower pt felt
cadenc turnaround sale growth would delay said continu feel buy rate
appropri valuat sat peer group ev/ntm sale time combin growth excess
peer group impli make compel invest multi-year basi axgn top-
line growth expect remain meaning peer even share continu declin concern
growth competit gener sell high growth name reach confluenc exist market size
concern take toll stock feel creat open generalist value-ori investor
attract long-term growth profil momentum driven investor take back seat suspect
mani investor enter name last sizabl pullback mid-teen exhaust posit
limit support share see less concern around quarter point mani investor take wait
see approach share move meaning higher believ like meet expect littl
move share higher investor see better consist execut
crux shift guidanc initi upgrad reliant sale forc dynam continu analysi
sale forc look size experi level repres determin rate growth
matur versu expect management guid choppier growth larg result delay realiz
product gain among matur repres gener churn sale forc territori split management
reiter confid updat guidanc appropri given base lower product level
seen sale forc difficult gain comfort given multipl misstep seen previous
figur sale forc analysi new month matur reach month matur
sheer rep count perspect compani ad fewer four addit seen
six seven respect somewhat concern drive greater market penetr larg driven
new rep could indic slow growth said compani need add five rep
reach state goal year end necessarili case compani schedul new
rep ad larg exist geographi strategi split territori rep reach sale target seem
current valuat continu feel risk/reward remain intact would buyer
level said expect see share move much higher management show consist execut restat
guidanc level share trade signific discount high growth med-tech group ntm ev/sal
rel high growth peer ntm ev/sal abl continu execut sustain
believ share progress move higher combin increas sale expand multipl
model chang chang model time
valuat rate buy pt base estim month revenu estim
believ grow sale forc headcount combin higher proport matur rep lead
improv sale consist sale execut multipl high growth med-tech peer grow
lower rate given challeng seen late feel discount multipl
group appropri time risk rate pt includ sale forc dynam product distributor sale
forc dynam competit larger player fda regulatori risk clinic trial success ip expir
ntm entxentneutr medicaltcmdbuy pt medicalwmginot factset data btig ptpricemarket cap
incom etot y/i sale oper incom incom tax expens net incom share net net oper expens btig estim compani report
revenu growthav y/i y/i y/i y/i q/q q/q q/q q/q sale rep etot distribut chanelmatur rep rep new rep quarter rep rep month rep rep rep accountsnew btig estim compani report
preview model revenu y/i adjust ebitda adjust lp
consensu estim call revenu adjust ebitda adjust lp
put us in-lin street top bottom line product categori estim
consum revenu y/i equip revenu y/i
come believ investor primarili focus close integr solsi follow
sharehold vote late septemb acquisit complet came littl later expect due time
question sec note resolv past quarter follow legal regulatori
compon investor interest hear oper management intend leverag structur two sale
channel know split sale forc specialti surgic advanc wound give
greater channel depth time near-term could slight disrupt next quarter
around sale forc integr sale forc educ relat new product although expect retain
rep creat sale forc greater peopl legaci time management
state goal grow sale forc rep annual within respect area combin rep across
entir organ believ aggress time-frame allot direct appropri sale
channel compet scale necessari wound care intend scale heard
concern investor type invest growth-ori compani would surpris us
see take addit equiti necessari step invest believ share would actual
perform well ad liquid
reflect previou quarter note came slightli expect due suppli compon
shortag shortag like persist inventori build pent-up demand
previou quarter order help buoy result order cancel due stock-out
delay shortag last quarter seem impact order either unabl deliv product quickli
plan
earli clinic feedback nexu posit devic offer oper effici within variou clinic
set look earli feedback management around sale cycl evalu usag pattern last
quarter management relay us proactiv approach idn want evalu nexu
competit offer suggest earli clinic momentum management caution evalu could take time
though broader system contract could
current share trade ntm ev/sal vs peer trade ntm ev/sal believ discount
peer present opportun investor given expect improv growth sustain
believ share could see multipl expans closer similar growth compani trade closer
model chang leav model unchang time
valuat rate buy pt base estim month revenu estim
grow revenu compound-annual-growth-rate inclus solsi compar peer higher growth rate
warrant premium compar orthoped wound care compani believ maintain
sustain growth share appreci risk rate pt competit limit suppli theraskin integr
risk associ solsi smaller scale rel competit limit liquid capit need
ntm therapeuticsaniknot lifesciencesiartbuy surgicalrtixnot medicalwmginot factset data btig research estim ptpricemarket cap bp/e ex-amortev/salescagr
incom etot y/i sale oper incom incom tax expens loss continu incom loss discontinu net incom share net incom share net oper expens btig research estim compani report
revenu etot woundy/i growth growth growth woundq/q growth growth growth woundpercentag btig research estim compani report
preview model revenu y/i ebitda lp consensu
estim revenu ebitda adjust lp put us line street
outsid lesser lp product categori estim revenu y/i orthobiolog
y/i spinal fusion hardwar
deliv consist revenu growth hsd past two quarter dd revenu growth
enter multipl new product multipl new distributor pick-up new instrument set give management
confid abil meet increas hsd expect said share challeng
much past quarter suspect part due broader macro-dynam market sector rotat
med-tech shift away momentum even dynam surpris spne share perform given
alreadi inexpens valuat ntm ev/sal consist execut specif compani believ
could caution around comp face notabl ou high combin concern
unwarr view spne capit posit continu find share attract believ investor
overlook small-cap spine player
specif quarter see less upsid number given tougher comp categori like
outperform believ could orthobiolog recal broadli launch osteostrand line product earli
believ begin hit stride separ within spinal hardwar highlight launch
marin outrigg revis system shorelin rt cervic system smaller launch expect marin
mi system biggest driver hardwar growth beyond difficult pars lift
expect get new product launch rel new instrument set new distributor collect
benefit compani case previou quarter also cite intra-quart survey work
note share gain smaller privat player lifespin well bullish
procedur environ expect recent caught nass management confid abil
deliv expect
beyond top-lin dynam see limit gross margin expans near-term much gm lift saw earlier
year expect remain stagnant inventori drawdown legaci product run-through rest
oper expens expect remain check leverag could gain like event
enter share trade ntm ev/sal vs peer trade ntm ev/sal signific discount
surpris share fare past quarter given numer product roll
combin instrument set deploy management tone encourag spne abil grow
sustain multipl overal spine market
model chang leav model unchang time
valuat seaspin rate buy price target base ev/sal multipli month
revenu estim risk rate includ execut amongst distributor sale forc price pressur
within spine vendor consolid increas competit within spinal implant industri
ntm lifesciencesiartbuy surgicalrtixnot factset data btig research estim ex-amortev/salescagrcompanytickerr ptpricemarket cap
incom etot y/i sale oper incom incom tax expens net incom share oper expens btig research estim compani report
revenu fusion fusion fusion fusion btig estim compani report
preview model revenu y/i y/i ex-licens payment lp consensu
expect call revenu lp put us line consensu quarter respect
busi segment model revenu iuni/iduo/itot cr y/i itot ps revenu
y/i itot hip revenu y/i geograph split call us revenu
y/i ou revenu y/i geograph revenu exclus royalti
stock roller coaster ride ralli sever hundr percent first two quarter
year sell follow disappoint result revenu guidanc cut base increas
number insur denial disappoint guidanc uncertainti around revenu growth would abl
turn around led us downgrad share follow initi sell-off share ralli somewhat settl end
quarter
look toward result number move piec factor perform come print
import factor view updat insur denial compani saw impact result
given chang guidanc call saw product revenu growth guidanc reduc growth
flat estim impact revenu expect impact beyond
expect intra-quart impact denial listen updat resolut payor
management describ view situat like error part aetna aet rate compani
could confus patient-specif instrument cut guid knee implant polici
review management view indic like near-term resolut issu said given prior experi
reimburs ci rate feel unlik full resolut come sever month
beyond payor dynam perform revenu categori notabl revenu scrutini chiefli
continu launch itot hip on-going perform struggl ou look itot hip full launch
delay expect revenu continu de minimi broader top-line
look sign potenti greater ramp upon full launch ou reimburs continu challeng ou
adopt see chang forecast continu declin revenu region
top-line expens management particular interest quarter grow difficulti gener top
line growth abil compani maintain expens increasingli import compani
done well recent quarter bring margin reduc expens resolv payor issu us abroad
continu activ win new doctor drive cost stress compani abil maintain
share level initi post earn sell-off recoveri feel investor someth
hold pattern bull could point continu potenti upsid itot hip reduc cash burn
combin inexpens valuat someth could view transitori event time bear
look aetna issu anoth instanc payor difficulti becom pattern oppos one-
event conflat creat situat like rang bound issu fulli
resolv return growth
model chang leav model unchang time
valuat rate neutral continu view line product possess clinic
valu payor issu neg impact revenu sizabl challeng ahead see limit upsid share despit
inexpens valuat btig publish price target neutral-r stock risk rate upsid
includ rapid reimburs decis aetna rapid uptak knee implant acceler adopt
ihip greater expect expens reduct downsid risk includ worsen payor dynam competit
shift robot within orthoped gross margin improv materi share dilut
ntm lifesciencesiartbuy surgicalrtixnot factset data btig research estim ptpricemarket cap bp/e ex-amortev/salescagr
incom etot y/i sale time oper incom incom tax expens net incom share oper expens btig research estim compani report
revenu product product product revenuesourc btig estim compani report
rel valuat larg mid small-cap medic technolog
track ntm ev/sal valuat past year large-cap mid-cap small-cap medic technolog
compani compar differ valuat see med-tech
valuat fall rel gaug sentiment investor interest space
large-cap med-tech name trade ntm ev/sal septemb spread larg cap
med-tech multipl turn closer like move even octob med-tech
under-perform broadli mid-cap multipl trade ntm ev/sal still premium level seen
revert back histor norm small cap med-tech multipl contract
ntm ev/sal end quarter ntm ev/sal roughli equival
figur spread larg cap mid-cap small cap med-tech ev/sal ev/sal
medic confer note
figur confer recent upcom quarter
datelocationconferenceapplic coverag illamerican societi retin vega nvamerican societi surgeri hand vega nvwild wound illamerican orthoped foot ankl societysyk franceeuropean societi cataract refract surgeonsalc illnorth american spine societysyk datelocationconferenceapplic coverag vega nvsymposium advanc wound fall san francisco caamerican academi ophthalmologyalc york nyamerican shoulder elbow surgeonssyk francisco cacongress neurolog surgeonssyk tnmusculoskelet new ventur flcurrent concept joint replacementsyk
btig cover compani mention report
appendix analyst certif import disclosur
